Omeros, the privately held Seattle-based drug developer, said today it received $3.1 million in equity financing and grants from The Stanley Medical Research Institute to continue animal testing of a treatment for schizophrenia. Omeros previously received $2.6 million from the institute when it reached an agreement to begin the schizophrenia work in December 2006. Earlier this month, Omeros received a $465,000 grant from the Michael J. Fox Foundation for Parkinson’s Research.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
